The Puget Sound research community received a rare visit from a very popular individual in the pharmaceutical world. The institution was visited by Joe Biden, the Vice President of the country. Seattle Genetics is one of the growing communities in the area that have set it apart.
Seattle Genetics is a Bothell based biotechnology institution that is working very hard to widen the use of its first product in the market and at the same time enlarge its drug pipeline. The company is also looking to embark of a new hiring spree to get more reliable professionals.
The company is trying its best to make a difference in the lives of individual suffering from cancer. At the moment, the company is trying to commercialize Adcetris, its only drug in cancer treatment. According to the CEO of the institution, Dr. Clay Siegall, the drug is being tested on more than seventy types of lymphomas.
To ensure that it succeeds in its efforts, Seattle is conducting phase 3 clinical trials that use their drug as the frontline treatment for new cases of Hodgkin lymphoma. At the end of the day, the results of the trial will have a great impact on the institution.
The new product from the company, Adcetris is mostly used when the doctors are trying to fight lymphomas. In 2015, the drug did quite well in its sells, especially in the United States and in Canada. The institution has a partner, known as Takeda Pharmaceuticals, and it has managed to sell the product in other countries in the world.
Adcetris is actually one of the products from the institution. At the moment, there are twelve drugs that are being developed, Adcetris not included. The second drug, known as 33A will be expected to get to phase 3 trials before the years comes into an end, and it will be used to cure acute myeloid leukemia. There is a special drug for breast cancer and another one for bladder cancer, and they are expected to be introduced in the market soon.
Dr. Clay Siegall is the CEO and Founder of Seattle Genetics. He is also the chairman of the institutions, and he has worked hard to raise capital and market the products from the company. He is very experienced in ecology, and he is a member of different boards.